Company News

  • 10 September 2019

    FDA approves Boehringer’s Ofev for rare lung disease

    The US Food and Drug Administration (FDA) has approved Boehringer Ingelheim’s Ofev (nintedanib) medicine to slow the rate of pulmonary function decline in systemic sclerosis-associated interstitial lung disease (SSc-ILD) patients.

Close
Close
Close